New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 6 #6/7 July 15, 2001


State-of-the-Art in the Management of Cancer

BLADDER CANCER-PART IV
PROGNOSIS AND TREATMENT OF BLADDER CANCER BY STAGE AND GRADE

Treatment of Bladder Cancer
  • Superficial Bladder Cancer
    • Low-risk superficial bladder cancer
    • High-risk superficial bladder cancer
  • Carcinoma in situ (CIS)
  • Muscle-Invasive Disease
  • Recurrent Disease
  • Upper Urinary Tract TCC
  • Metastatic Bladder Cancer
Prognostic and Predictive Factors and Disease Monitoring
  • Surveillance Requirements
  • Clinical Factors
  • Molecular Markers
    • p53
    • Cell-cycle modulators
    • Integrins

Meeting Coverage

GENE THERAPY OF CANCER-PART II
MECHANISM-BASED AND OTHER
TREATMENT OPTIONS FROM
THE 9TH INTERNATIONAL CONFERENCE
ON GENE THERAPY OF CANCER,
SPONSORED BY SIDNEY KIMMEL CANCER CENTER,
SAN DIEGO, CA, DECEMBER 7-9, 2000

Tumor Suppressor Compensation/Enhancement/Targeting

  • p53
    • Replacement of a defective p53 gene
    • Cytolytic agents targeting p53-deficient cancer cells
  • mda-7
  • pHyde
  • p27
Inhibition/Knock-Out of Promoters of Tumor Growth
  • Sex hormone-binding globulin (SHBG)
  • T-ag of Human Polyomavirus BK (BKV)
  • K-ras
Growth Factor Suppression
  • Transforming growth factors (TGF)
Antiangiogenic Gene Therapy
  • In vivo Delivery and Expression of Endostatin
  • Tumor Suppressor Activity and Inhibition of Angiogenesis
Suicide Gene-based Approaches
  • Gene-directed Enzyme Prodrug Therapy (GDEPT)
    • HSVtk/ganciclovir
    • Cytosine deaminase/5-fluorocytosine (CD/5-FC)
    • Cytochrome P450/cyclophosphamide (CYP/CP)
    • Horseradish peroxidase/indole-3-acetic acid (HRP/IAA)
    • Carboxylesterase/irinotecan (CE/CPT-11)
    • Methioninase/selenomethionine (METase/SeMET)
    • Beta-glucuronidase/HMR 1826
  • Self-Deleting Vectors
Other Direct Cytotoxicity Approaches
  • Transfer of Genes Encoding Viral Fusogenic Membrane Glycoproteins
  • Tumor-specific Activation of dsRNA-dependent PKR
  • Attenuated, Replication-competent Adenoviruses
Potentiation of Conventional Therapy
  • Chemotherapy Sensitization
  • Radiation Therapy Sensitization
  • Combined Chemo/Radiotherapy Sensitization
  • Protection of Critical Host Tissues
Cell Marking Studies

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887